Flagship Ventures Management

Latest statistics and disclosures from Flagship Pioneering's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are MRNA, SANA, OMGA, FHTX, DNLI, and represent 98.37% of Flagship Pioneering's stock portfolio.
  • Added to shares of these 1 stock: SYRS.
  • Reduced shares in these 1 stock: DNLI (-$20M).
  • Flagship Pioneering was a net seller of stock by $-20M.
  • Flagship Pioneering has $1.5B in assets under management (AUM), dropping by 15.04%.
  • Central Index Key (CIK): 0001400240

Tip: Access up to 7 years of quarterly data

Positions held by Flagship Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Flagship Pioneering

Flagship Pioneering holds 7 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Moderna (MRNA) 67.6 $1.0B 9.7M 106.56
 View chart
Sana Biotechnology (SANA) 16.4 $250M 25M 10.00
 View chart
Omega Therapeutics (OMGA) 7.0 $107M 29M 3.65
 View chart
Foghorn Therapeutics (FHTX) 5.6 $85M 13M 6.71
 View chart
Denali Therapeutics (DNLI) 1.8 $28M -41% 1.4M 20.52
 View chart
Seres Therapeutics (MCRB) 1.2 $18M 23M 0.77
 View chart
Syros Pharmaceuticals (SYRS) 0.5 $6.9M 1.3M 5.35
 View chart

Past Filings by Flagship Pioneering

SEC 13F filings are viewable for Flagship Pioneering going back to 2016

View all past filings